Phase 1 trial suggests benefit of psilocybin in OCD treatment
The Brown University Psychopharmacology Update June 28, 2026 DOI: 10.1002/pu.31474 via OpenAlex
Summary
AI-generated from the abstractRepeated high doses of psilocybin reduced obsessive-compulsive disorder symptoms more effectively than low doses or placebo in a Phase 1 trial with 15 patients. Psilocybin was generally well-tolerated, with no serious adverse events reported.
Study at a glance
| Characteristics | Phase 1 trial Peer reviewed |
|---|---|
| Sample size | 15 |
| Population | Patients with obsessive-compulsive disorder |
| Intervention | Psilocybin |
| Dose | high-dose, low-dose |
| Topics | Psilocybin |
| Keywords | Placebo Adverse effect Hallucinogen Clinical trial |
| Key finding | Repeated high-dose administration of psilocybin was more effective than low-dose psilocybin or placebo in reducing OCD symptoms. |
Abstract
A Phase 1 trial comprising 15 patients has found that repeated high‐dose administration of psilocybin was more effective than low‐dose psilocybin or placebo in reducing symptoms of obsessive‐compulsive disorder (OCD). Psilocybin was generally well‐tolerated, with no reports of serious adverse events.